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A b s tra c t
Background: Plexin Dl is expressed on both tumor-associated endothelium and malignant cells 
in a number of clinical brain tumors. Recently we demonstrated that Plexin Dl expression is 
correlated with tumor invasion level and metastasis in a human melanoma progression series. The 
objective of this study was to examine whether Plexin Dl might be clinically useful as a pan-tumor 
vessel and pan-tumor cell target in solid tumors.
Methods: We examined Plexin D 1 expression in clinical solid tumors (n = 77) of different origin, 
a selection of pre-malignant lesions (n = 29) and a variety of non-tumor related tissues (n = 52) by 
immunohistochemistry. Signals were verified in a selection of tissues via mRNA in situ hybridization.
Results: Plexin Dl is abundantly expressed on both activated established tumor vasculature and 
malignant cells in the majority of primary and metastatic clinical tumors, as well as on macrophages 
and fibroblasts. Importantly, in non-tumor related tissues Plexin Dl expression is restricted to a 
subset of, presumably activated, fibroblasts and macrophages.
Conclusion: We demonstrate that Plexin Dl is in general ubiquitously expressed in tumor but 
not normal vasculature, as well as in malignant cells in a wide range of human tissues. This 
expression profile highlights Plexin Dl as a potentially valuable therapeutic target in clinical solid 
tumors, enabling simultaneous targeting of different tumor compartments.
Background
Interference with a tumor's blood supply is an attractive 
approach to inhibit tum or growth and dissemination. 
Thereto, many research focused on targeting the ang­
iogenic process via inhibition of the Vascular endothelial 
Growth Factor (VEGF-A) pathway. Despite promising 
results in animal tum or models in which anti-VEGF ther­
apy translates into potent anti-tumor effects [1-3], imple­
m entation of these therapies for a number of tum or types 
in the clinic has now learned that they, either or no t in 
combination with chemotherapy, do increase quality of 
life or modestly prolong survival [4-7], bu t lack curative 
effects [8,9]. This discrepancy may be partly due to the 
high heterogeneity of the vasculature [10-12]: in estab-
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lished clinical tumors all possible maturation stages may 
be represented, only a small fraction of which may be sus­
ceptible to VEGF inhibition [13]. This situation contrasts 
that in fast growing animal tumors in which the entire 
population of tum or vessels may be in a synchronized 
maturation stage. In addition, we and others described 
that in organs with intrinsically high vessel densities, 
tumors and metastases are able to grow in an angiogen- 
esis-independent fashion via co-option of pre-existing 
blood vessels [14-18]. This provides tumors with a route 
of escape which makes them (partially) unsusceptible to 
anti-angiogenic compounds. Even more, anti-angiogen- 
esis may drive a shift in brain tumors from an angiogenic 
to a co-opting phenotype [19-21]. Therefore, vascular tar­
geting therapy in which the existing tum or vascular bed, 
angiogenic or pre-existent, is attacked with the aim to 
induce acute tumor-specific coagulation may be an attrac­
tive additional approach to deprive a tum or from blood 
supply. To apply vascular targeting therapies, targetable 
markers that discriminate tum or vessels from normal vas­
culature are needed. We previously described that Plexin 
D1 (PLXND1) could be such a target [22].
PLXND1 belongs to a family of large transmembrane pro­
teins that are receptors for neuropilins and semaphorins 
[23,24]. Plexins are involved in regulation of axonal pat­
terning during embryonic development [25-28]. Apart 
from neuronal cells, PLXND1 is also expressed by vascular 
endothelial cells during embryogenesis [29] and is of piv­
otal importance for vascular patterning, as illustrated by 
the fact that PLXND1 knock-down in mice and zebrafish 
results in abnormal development of the cardiovascular 
system [30-32].
We previously demonstrated that PLXND1 is also specifi­
cally expressed on vascular endothelium during tumor- 
associated angiogenesis in a mouse xenograft model of 
cerebral melanoma metastasis and in a number of hum an 
brain tumors, both of primary and metastatic origin [22]. 
Importantly, expression of this protein was also found on 
tum or cells in these tumors [22], and this expression cor­
relates with malignancy grade in a hum an melanoma pro­
gression series: whereas PLXND1 is abundantly expressed 
in both invasive primary and disseminated melanomas, 
both in the vasculature and in tum or cells, its expression 
was absent in benign melanocytic lesions and melanomas 
in situ, except for expression on macrophages and fibrob­
lasts [33].
PLXND1 contains in its intracellular dom ain consensus 
Rac/RhoA signalling motifs [29], suggestive of a role in 
cytoskeletal rearrangements and cell motility, processes 
which are fundamental for both tum or angiogenesis and 
metastasis. PLXND1 may thus be functionally involved in 
tum or development in multiple ways.
The expression profile of PLXND1 suggests that it may be 
a valuable tum or target for established solid tumors, 
allowing simultaneous targeting of different tum or com­
partments, i.e. vessels and tum or cells. To examine 
whether PLXND1 might be clinically useful as a pan­
tum or vessel and pan-tumor cell target in solid tumors we 
analyzed PLXND1 expression in a wide range of hum an 
tumors of different origin, various pre-malignant and 
non-tum or related tissues by immunohistochemistry and 
mRNA in situ hybridization.
M ethods  
Tissue samples
Primary and metastatic tum or tissues of different origin (n 
= 77), among them 15 paired samples of hum an primary 
and metastatic lesions and various pre-malignant lesions 
(n = 29), were selected from the archives of the Depart­
m ent of Pathology and Radiology of the Radboud Univer­
sity Nijmegen Medical Centre. Furthermore, non-tum or 
related tissues (n = 52) were obtained. The study was per­
formed according to the guidelines of the Code for proper 
secondary use of hum an tissue in the Netherlands (Ver­
sion 2002, Federation of Biomedical Scientific Societies, 
http://www.federa.org).
Im munohistochemistry
After deparaffinization and blocking of endogenous per­
oxidase activity, antigen retrieval was performed by treat­
m ent with pronase according to standard protocols [33]. 
Non-specific binding sites were blocked by incubation 
with 20% normal horse serum. Slides were incubated for 
1 hr with single domain antibody A12, which was previ­
ously selected against a PLXND 1-specific peptide [22]. 
A12 was detected by sequential incubations with the 
mouse anti-VSV-G P5D4, biotinylated anti-mouse IgG 
(Vector, Burlingame, CA), and avidin-biotin peroxidase 
complex (Vector). Peroxidase was visualized by the 3- 
amino-9-ethylcarbazole (ScyTek, Logan, UT) peroxidase 
reaction, with haematoxylin as counterstain. All incuba­
tions were performed at room temperature. Blood vessel 
origin was confirmed by endothelial stainings on serial 
sections with anti-human CD31 antibody (DAKO, Glos- 
trup, Denmark).
In a selection of tissues, macrophage identity was con­
firmed by double staining for PLXND 1 and CD68. In 
short, the above mentioned avidin-biotin peroxidase pro­
cedure was used to detect PLXND1 via rabbit anti-VSV-G 
antiserum (Sigma Chemical Co., Zwijndrecht, The Neth­
erlands). Following visualization, avidin-biotin was 
blocked according to standard protocols. Slides were suc­
cessively incubated with normal horse serum, mouse anti­
hum an CD68 antibody (DAKO) overnight at 4°C, bioti- 
nylated anti-mouse IgG (Vector) and avidin-biotin alka­
line phosphatase (AP) complex (Vector) at RT. AP was
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visualized with a mixture of naphthol phosphate (Sigma), 
levamisole (Sigma), and Fast Blue (Sigma).
PLXND1 mRNA In Situ Hybridization
To explore whether the PLXND1 transcript is also specifi­
cally present in malignant tissues, we performed mRNA in 
situ hybridizations on 28 of the 158 paraffin-embedded 
tissues analyzed by immunohistochemistry (malignant 
lesions, n  = 15; non-tum or related samples, n  = 13) as pre­
viously described [22]. In brief, digoxigenin-labelled 
sense and antisense hum an PLXND1 RNA probes, located 
in the 3'-untranslated region, were generated by in vitro 
transcription from a PLXND 1 PCR product which was 
flanked by T7 and T3 promoters as described [29]. Follow­
ing deparaffinization, 4 |im  tum or sections were treated 
with proteinase K (Roche, Almere, The Netherlands) at 
37°C for 15 minutes and post-fixed in formaldehyde. 
Non-specific binding sites were blocked by incubation 
with acetic anhydride (Sigma) at room temperature. Tis­
sues were hybridized with digoxigenin-labelled RNA 
probes at 63° C with 200 ng/ml probe. Single stranded 
non-hybridized RNA was degraded with RNAse T1 (2 
units/ml) at 37°C for 30 minutes. After subsequent pre­
incubation with normal sheep serum, the slides were 
incubated with alkaline phosphatase-conjugated sheep 
anti-digoxigenin antibody (Roche) at room temperature 
for 1 hour. Alkaline phosphatase was visualized using 
nitro blue tetrazolium (NBT; Roche) and 5-bromo-4- 
chloro-3-indolyl phosphate (BCIP; Roche) as substrate 
with nuclear fast red as counterstain. Specificity of hybrid­
izations was verified by performing control hybridiza­
tions with sense probe.
Results
To explore whether PLXND1 may be clinically useful as a 
pan-tumor endothelium and a pan-tumor cell target we 
examined the expression profile of this protein in a large 
variety of hum an tissue samples. As summarized in Table 
1, PLXND1 is abundantly expressed in both the vascula­
ture and malignant cells in the majority of clinical tumors, 
whereas in pre-malignant lesions the protein is present at 
lower levels or, like in non-tum or related tissues, almost 
completely absent (Table 2). Figure 1 shows vascular 
(arrows) and tum or cell expression of PLXND1 in repre­
sentative samples of brain metastasis of adenocarcinoma 
(A), glioblastoma multiforme (B), neuro-endocrine lung 
tum or (C), ovarian adenocarcinoma (D), and prostatic 
urothelial cell carcinoma (E). The insets in A and B show 
corresponding in situ hybridization signals. Vascular and 
tum or cell-associated PLXND1 expression was absent in 3 
out of 5 medullary breast carcinomas, one out of 5 cervi­
cal squamous cell carcinomas, and all examined vulvar 
squamous cell carcinomas (Table 1). A representative 
sample of vulvar squamous cell carcinoma is shown in fig­
ure 1F. In addition, two low grade astrocytomas showed
infrequent vascular and tum or cell-associated PLXND 1 
expression (Table 1). As shown in figure 2A through F no 
significant differences in staining pattern and intensity of 
vascular structures (arrows) and malignant cells could be 
observed between primary ductal breast carcinoma (A) 
and a corresponding lymph node metastasis (B), colon 
adenocarcinoma (C) and a corresponding liver metastasis 
(D) and renal cell carcinoma (E) and a corresponding 
brain metastasis (F, the inset shows corresponding in situ 
hybridization signal).
To examine whether PLXND1 is expressed on angiogenic 
vessels under physiological conditions, we also investi­
gated expression in endometrium. In 3 out of 5 prolifera­
tive phase endometria some vessels stained positive for 
PLXND1 (Table 2). Figure 2G and 2H show lack of 
PLXND1 protein and transcript (insets) in normal hum an 
cerebral cortex and heart tissue. The granular staining pat­
tern in cerebral neurons (G) and cardiac myocytes (H) is 
presumably due to aspecific binding of single domain 
antibodies to lipofuscine as this is observed with other 
non-related single domain antibodies too (not shown). 
Apart from tumor-associated endothelium and tumor 
cells, PLXND1 expression was also observed in subsets of 
fibroblast- and macrophage-like cells in both tum or sam­
ples and pre-malignant and non-tum or related tissues. 
Identity of macrophages was confirmed by double stain­
ing a selection of analyzed tissues for PLXND1 and CD68 
(not shown).
Discussion
In previous work we showed that PLXND1 is expressed in 
endothelial cells during developmental and tumor-associ­
ated angiogenesis [22,29]. Besides vascular expression, 
high PLXND1 expression was also found on tum or cells in 
cerebral melanoma metastases. Whereas a role of 
PLXND1 in vessel patterning during development is well 
established [30-32], the functional consequences of 
PLXND1 expression on tum or cells and vessels are less 
clear. We recently demonstrated that PLXND1 expression 
is correlated with tum or invasion and metastasis in a 
hum an melanoma progression series [33]. However, the 
PLXND1 ligands Semaphorin 3E and 4A inhibit, rather 
than promote, (tumor) angiogenesis [33,34]. Moreover, 
Semaphorin 3E even exhibits anti-tumor and anti-meta­
static properties [33,35].
Here we show that PLXND1 is expressed at high levels on 
activated established tum or vasculature in a variety of pri­
mary and metastatic hum an malignancies, whereas in 
non-tum or related tissues PLXND1 expression is restricted 
to a subset of, presumably activated, fibroblasts and mac­
rophages. These results are in agreement with our previ­
ous observations in clinical brain tumors of different 
origin [22] and a series of cutaneous melanocytic lesions
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M a lig n a n t tis s u e P L X N D I  e x p re s s io n R e m a rk s
Endothelial cells Tumor cells Subset o f  macrophages Subset o f fibroblasts
Paired samples
Medullary breast carcinoma
(n = l)
- - + + Plasma cells also positive
Lymph node metastasis 
(n = l)
Subset - + n.d.
Ductal breast carcinoma
(n = 8)
+ + + + Some plasma cells also 
positive
Lymph node metastasis 
(n = 8)
+ + + +
Adenocarcinoma o f colon + + + +
(n = 4)
Liver metastasis (n = 4) + + + +
Alveolar soft part sarcoma of + + n.d. n.d.
fem ur (n = l)
Brain metastasis (n = l) + + n.d. n.d.
Renal cell carcinoma (n = 1) + + n.d. n.d.
Brain metastasis (n = 1) + + n.d. n.d.
N on-paired samples
Adenocarcinoma of coecum 
(n = l)
+ + + -
Adenocarcinom a of 
oesophagus (n = l)
+ + + -
Adenocarcinom a of ovary 
(n = l)
Subset + + +
Adenocarcinom a of prostate 
(n = l)
+ + - -
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Adenocarcinoma o f rectum 
(n = 5)
+ + + +
Brain metastasis o f 
adenocarcinoma (n = 4)
+ + n.d. n.d.
Liver metastasis o f + + + +
adenocarcinoma colon 
(n = 8)
O vary metastasis o f - +
adenocarcinoma colon
(n = 1)
Low grade astrocytom a 
(n = 2)
Subset Subset n.d. n.d.
G lioblastoma M ultiform e
(n = 3)
+ + n.d. n.d.
Medulloblastoma (n = 1) + + n.d. n.d.
Neuro-endocrine tu m o r o f 
lung (n = 2)
+ + + n.d.
Medullary breast carcinoma 
o f (n = 4)
+ + + + 2 samples negative vessels 
and tu m o r cells
Lymph node metastasis o f Subset +
ductal breast carcinoma 
(n = l)
Squamous cell carcinoma o f Subset + +
cervix (n = 5)
Squamous cell carcinoma o f - - + +
vulva (n = 5)
U rothelia l cell carcinoma o f + + +
prostate (n = 2)
+, corresponding cell type expresses P LX N D l 
-, P L X N D l expression is absent in corresponding cell type 
n.d., corresponding cell type is no t detected
representing different stages of melanoma progression
[33]. So, for subsets of tum or types in which vessel activa­
tion has occurred, PLXND1 may be a valuable candidate 
protein for vascular targeting approaches. Indeed, the 
anti-PLXNDl single domain antibody A12 homes to and 
accumulates in tum or vessels [22].
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agents directed against molecules of which expression is 
restricted to vessels in early stages of angiogenesis. Exam­
ples are the L19 single chain antibody, directed against the 
ED-B fragment of fibronectin which targets vasculature in 
actively growing tumors [36], whereas this single chain
1 sample negative vessels 
and tu m o r cells
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T issu e P L X N D l e x p re s s io n R e m a rk s
Endothelial cells Subsets o f  macrophages Subsets o f  fibroblasts
Pre-malignant samples
Ductal carcinoma in situ o f breast 
(n = 5)
+ + + W eak staining o f tu m o r cells
Lobular carcinoma in situ o f breast
(n = 3)
W eak + + W eak staining o f tu m o r cells
Vulvar intraepithelial neoplasia 
(VIN)
Classic V IN  III, HPV negative
(n = 5)
- + +
Classic V IN  III, HPV positive 
(n = 8)
- + +
Differentiated V IN  III (n = 8) - + n.d.
N on-tum or related samples
Bladder (n = I) - + -
Blood vessel
Atherosclerosis (n = 6) - + -
Fatty streaks (n = 1) - + -
Bone m a rrow  (n = 2) n.d. - -
Brain
C o rte x  (n = 1) - n.d. n.d. Some neurons perinuclear staining
A lzheim er and C A A  (n = 1) - n.d n.d.
Multiple Sclerosis (n = 2) - n.d n.d.
Breast
Norm al breast (n = 2) - - - Some epithelial cells perinuclear 
staining
Ductal hyperplasia (n = 1) - + - Focal epithelial cells perinuclear 
staining
Endometrium
Proliferation phase (n = S) Subset (n = B) + n.d.
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Secretion phase (n = 4) - + n.d.
Secretion/m enstruation phase _ + n.d.
(n = 1)
Endometriosis interna (n = l) - + n.d.
H eart (n = l) - n.d n.d Myocytes perinuclear staining
Large intestine (n = l) - + + Some epithelial cells perinuclear 
staining
Liver (n = l) - + n.d. Some hepatocytes perinuclear 
staining
Lung (n = 2) - + n.d.
Oesophagus (n = l) - + -
Pancreas (n = l) - n.d n.d. Perinuclear staining Islets o f 
Langerhans
Pituitary gland (n = l) - n.d. n.d. Some epithelial cells perinuclear 
staining
Prostate (n = l) - - n.d. Some epithelial cells perinuclear 
staining
Small intestine (n = l) - + + Some epithelial cells perinuclear 
staining
Spleen (n = l) - + n.d.
Thyro id  gland (n = l) - + n.d. Some epithelial cells perinuclear 
staining
Vulva
Norm al vulva (n = 6) - + +
Lichen sclerosus (n = 6) - + +
+, corresponding cell type expresses P LX N D l 
-, P L X N D l expression is absent in corresponding cell type 
n.d., corresponding cell type is no t detected
antibody is unable to detect quiescent endothelium in 
low grade malignancies [37]. Targeted radiotherapy with 
radiolabeled RGD peptides, recognizing integrin avP3 on 
newly formed endothelial cells, led to reduced growth of 
xenografts in mouse models of cancer [38-40]. Further­
more, chimeric proteins, consisting of antibodies against 
the tum or vessel marker vascular cell adhesion molecule 1 
(VCAM-1), fused to soluble Tissue Factor, induced tumor 
specific blood clotting, tum or necrosis and growth delay 
in different xenograft models [41].
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Due to vessel heterogeneity in tumors [10-12,42] it is 
unlikely that one single marker will behave as a targetable 
pan-tumor-endothelial antigen, but appropriate mixtures 
of different tum or vessel targeting agents, including anti- 
PLXND1 antibodies, may allow specific targeting of the 
majority of tum or vessels. For instance, to effectively 
starve tumors like low grade gliomas, which (partly) 
thrive on quiescent vasculature, targeting agents that rec­
ognize co-opted vessels in infiltrative tum or areas need to 
be developed. It remains to be seen whether such targets
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Figure l
PLXNDl expression in represen ta tive  clinical tu m o r 
samples. Immunohistochemical analyses using a single 
domain antibody against PLXNDl (Magnification *200). 
PLXNDl is abundantly expressed in adenocarcinoma brain 
metastases (A), glioblastomas multiforme (B), neuro-endo­
crine lung tumors (C), an ovarian adenocarcinoma (D), and 
prostatic urothelial cell carcinomas (E). The arrows point at 
PLXNDl-positive vasculature. PLXNDl is absent in both 
tumor vasculature (arrowheads) and tumor cells in vulvar 
squamous cell carcinomas (F). The insets in A and B show 
corresponding PLXNDl mRNA in situ hybridization analyses 
(Magnification *200).
can be identified and, if so, whether such strategy holds 
promise for treatment of brain tumors, as it will include 
some toxicity for interspersed normal brain in infiltrative 
tum or areas.
Apart from vascular PLXND1 expression in tumors, the 
protein is also abundantly expressed on tum or cells in a 
wide range of clinical solid tumors which reinforces this 
membrane protein as a tum or target, since it allows simul­
taneous targeting of different tum or compartments with 
one compound. Since all tum or metastases tested, except 
for one lymph node metastasis of a medullary breast car­
cinoma, expressed high levels of this protein, both on ves­
sels and tum or cells, a PLXND1-directed seek-and-destroy 
strategy may therefore indeed be feasible.
Figure2
PLXNDl expression in represen ta tive clinical 
(tum or) samples. Immunohistochemical analyses using a 
single domain antibody against PLXNDl (Magnification 
*200). PLXNDl is expressed at high levels in primary ductal 
breast carcinomas (A) and corresponding lymph node metas­
tases (B), colon adenocarcinomas (C) and corresponding 
liver metastases (D) and a renal cell carcinoma (E) and corre­
sponding brain metastasis (F). The arrows point at PLXNDl - 
expressing tumor vessels. PLXNDl is not detected in normal 
human cerebral cortex (G) and heart (H) tissue samples. The 
insets in F, G and H show corresponding PLXND1 mRNA in 
situ hybridization analyses (Magnification *200).
Despite its abundant expression in many different tumor 
types PLXND 1 was not expressed on tum or cells and ves­
sels in a subset of medullary breast carcinomas. Interest­
ingly, these relatively rare tumors generally have a 
favorable prognosis [43]. It is tempting to speculate that 
PLXND1 expression is generally correlated with increased 
malignancy grade. The only other tum or type in our series 
which lacked vascular and tum or cell-associated PLXND 1
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expression was vulvar squamous cell carcinoma. Because 
the increased microvessel density in these tumors suggests 
angiogenesis [44], the lack of PLXND1 on vessels in these 
tumors was unexpected [22]. Whether a lack of PLXND1 
expression on these vessels is related to a more mature 
state can only be speculated upon. Physiological angio- 
genesis in proliferative phase endometria has been 
described to occur mainly in a non-sprouting fashion via 
vessel elongation [45] which may explain the appearance 
of vascular PLXND1 in only a small subset of vessels in 
such tissue.
Conclusion
We demonstrated that PLXND1 is in general ubiquitously 
expressed in  tum or but no t normal vasculature, as well as 
in malignant cells in a wide range of hum an (tumor) tis­
sues. This expression pattern warrants further investiga­
tion towards PLXND1 as a therapeutic target in oncology.
C o m p e tin g  in terests
The authors declare that they have no competing interests. 
A u th o rs ' con tribu tions
IR performed the immunohistochemical analyses. KV car­
ried out mRNA in situ hybridization and assisted in the 
interpretation of the results. JR participated in the design 
of the study and provided general support. IR and WPJL 
were responsible for experimental design, interpretation 
of the results and writing the manuscript. All authors read 
and approved the final manuscript.
References
1. Mendel DB, Laird AD , X in  X , Louie SG, Christensen JG, Li G, Schreck 
RE, Abrams TJ, Ngai TJ, Lee LB: In v iv o  a n t itu m o r  a c t iv ity  o f  
SU  l l  248, a  n o ve l ty ro s in e  k inase in h ib i to r  ta rg e tin g  va scu la r  
e n d o th e lia l g ro w th  fa c to r  an d  p la te le t-d e r iv e d  g r o w th  fa c to r  
re c e p to rs : d e te rm in a t io n  o f  a  p h a rm a c o k in e tic /p h a rm a c o ­
d y n a m ic  re la tio n s h ip . Clin Cancer Res 2003, 9:327-337.
2. W ilhelm  SM, C arter C, Tang L, W ilk ie  D, McNabola A, Rong H, Chen 
C, Zhang X, Vincent P, McHugh M: B A Y  43-9006 e x h ib its  b ro a d  
s p e c tru m  o ra l a n t itu m o r  a c t iv ity  and  ta rg e ts  th e  R A F /M E K / 
ERK p a th w a y  and  re c e p to r  ty ro s in e  kinases in vo lve d  in 
tu m o r  p ro g re ss io n  and  angiogenesis . Cancer Res 2004, 
64:7099-7l09.
3. Presta LG, Chen H, O 'C onnor SJ, Chisholm V, Meng YG, Krummen 
L, W in k le r M, Ferrara N: H u m a n iz a tio n  o f  an a n ti-v a s c u la r  
e n d o th e lia l g r o w th  fa c to r  m o n o c lo n a l a n tib o d y  fo r  th e  th e r ­
ap y o f  so lid  tu m o rs  and  o th e r  d is o rd e rs . Cancer Res 1997, 
57:4593-4599.
4. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, 
Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST: S u n it in ib  versus  
in te r fe ro n  a lfa  in m e ta s ta t ic  re n a l-ce ll c a rc in o m a . N Engl J 
Med 2007, 356: l l5 - l2 4 .
5. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik
C, Chevreau C, Filipek M, Melichar B, Bajetta E: B e va c izu m a b  plus  
in te r fe ro n  a lfa -2a  fo r  t r e a tm e n t  o f  m e ta s ta t ic  re n a l ce ll c a r­
c in o m a : a ra n d o m is e d , d o u b le -b lin d  phase III t r ia l.  Lancet
2007, 3 7 0 :2 l03 -21 l l.
6. Hurw itz H, Fehrenbacher L, N ovotny W , C artw right T, Hainsworth 
J, Heim W , Berlin J, Baron A, Griffing S, Holmgren E: B e va c izu m a b  
plus ir in o te c a n , f lu o ro u ra c il,  and  le u c o v o rin  fo r  m e ta s ta t ic  
c o lo re c ta l ca n ce r. N Engl J Med 2004, 350:2335-2342.
7. Herbst RS, O 'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, H art 
L, Melnyk O, Ramies D, Lin M, Sandler A : Phase II s tu d y  o f  e ffica cy  
and sa fe ty  o f  b e va c izu m a b  in c o m b in a tio n  w ith  c h e m o th e r­
ap y  o r  e r lo t in ib  c o m p a re d  w ith  c h e m o th e ra p y  a lo n e  fo r  
t r e a tm e n t  o f  re c u r re n t  o r  re fra c to ry  n o n  sm a ll-c e ll lu n g  can­
ce r. J Clin Oncol 2007, 25:4743-4750.
8. Eichhorn ME, Strieth S, Dellian M: A n ti-v a s c u la r  tu m o r  th e ra p y : 
re c e n t advances, p itfa lls  a n d  c lin ica l pe rsp e c tive s . Drug Resist 
Updat 2004, 7:125-138.
9. Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, Zagzag
D, Fischer I, Raza S, Medabalmi P: A n tia n g io g e n ic  th e ra p y  using  
b e va c izu m a b  in re c u r re n t  h ig h -g ra d e  g lio m a : im p a c t on  
loca l c o n tro l and  p a tie n t su rv iva l. J Neurosurg 2009, 
1 10:173-180.
10. Roodink I, van der LJ, Kusters B, Wesseling P, Verrijp K, de W R, 
Leenders W : D e v e lo p m e n t o f  th e  tu m o r  va scu la r bed  in 
response  to  h yp o x ia -in d u c e d  V E G F -A  d iffe rs  f ro m  th a t  in 
tu m o rs  w ith  c o n s titu t iv e  V E G F -A  e xp re ss io n . fnt J Cancer
2006, 1 19:2054-2062.
11. Trepel M, Arap W , Pasqualini R: In v iv o  phage d isp la y  and  vascu­
la r  h e te ro g e n e ity : im p lic a tio n s  fo r  ta rg e te d  m e d ic in e . Curr 
Opin Chem Biol 2002, 6:399-404.
12. Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hana- 
han D: S tage -spe c ific  v a scu la r m a rk e rs  re ve a le d  by  phage d is­
p lay  in a m o u se  m o d e l o f  p a n c re a tic  is le t tu m o rig e n e s is . 
Cancer Cell 2003, 4:393-403.
13. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D: B ene­
fits  o f  ta rg e t in g  b o th  p e ric y te s  and  e n d o th e lia l ce lls  in th e  
tu m o r  v a s c u la tu re  w ith  k inase in h ib ito rs . J Clin Invest 2003, 
1 11:1287-1295.
14. Kusters B, Leenders W P, Wesseling P, Smits D, Verrijp K, Ruiter DJ, 
Peters JP, D er Kogel AJ, de Waal RM: V a s c u la r e n d o th e lia l 
g r o w th  fa c to r -A ( l6 5 )  indu ces p ro g re ss io n  o f  m e la n o m a  
b ra in  m e tas tase s  w ith o u t  in d u c tio n  o f  s p ro u tin g  an g iogen - 
esis. Cancer Res 2002, 62:341-345.
15. Leenders W P, Kusters B, de Waal RM: Vessel c o -o p tio n : h o w  
tu m o rs  o b ta in  b lo o d  su p p ly  in  th e  absence o f  s p ro u tin g  ang- 
iogenesis. Endothelium 2002, 9:83-87.
16. Leenders W , Kusters B, Pikkemaat J, Wesseling P, Ruiter D, Heersc­
hap A, Barentsz J, de Waal RM: V a s c u la r e n d o th e lia l g ro w th  fac­
to r - A  d e te rm in e s  d e te c ta b il i ty  o f  e x p e r im e n ta l m e la n o m a  
b ra in  m e ta s ta s is  in G D -D T P A -e n h a n c e d  M R I. Int J Cancer
2003, l05:437-443.
17. Dome B, Paku S, Somlai B, Timar J: V a s c u la r iz a tio n  o f  cu ta n e o u s  
m e la n o m a  in vo lve s  vessel c o -o p tio n  and  has c lin ic a l s ig n ifi­
cance. J Pathol 2002, 197:355-362.
18. Vermeulen PB, Colpaert C, Salgado R, Royers R, Hellemans H, Van 
Den HE, Goovaerts G, D irix  LY, Van Marck E: L iv e r  m e tastase s  
fro m  c o lo re c ta l a d e n o c a rc in o m a s  g ro w  in th re e  p a tte rn s  
w ith  d if fe re n t ang iogenesis  and  de sm op las ia . J Pathol 2001, 
195:336-342.
19. Leenders WP, Kusters B, Verrijp K, Maass C, Wesseling P, Heerschap 
A, Ruiter D, Ryan A, De Waal R: A n tia n g io g e n ic  th e ra p y  o f  c e r­
e b ra l m e la n o m a  m e tastase s re s u lts  in sus ta in ed  tu m o r  p ro ­
gress ion  v ia  vessel c o -o p tio n . Clin Cancer Res 2004, 
10:6222-6230.
20. van Kempen LC, Leenders W P: T u m o u rs  can a d a p t to  a n ti-a n g ­
io g e n ic  th e ra p y  d e p e n d in g  on  th e  s tro m a l c o n te x t:  lessons 
fro m  e n d o th e lia l c e ll b io lo g y . Eur J Cell Biol 2006, 85:61-68.
21. Claes A, Wesseling P, Jeuken J, Maass C, Heerschap A, Leenders WP: 
A n tia n g io g e n ic  c o m p o u n d s  in te r fe re  w ith  c h e m o th e ra p y  o f  
b ra in  tu m o rs  d u e  to  vessel n o rm a liz a tio n . Mol Cancer Ther
2008, 7:71-78.
22. Roodink I, Raats J, Zwaag B van der, Verrijp K, Kusters B, Van 
Bokhoven H, Linkels M, de Waal RM, Leenders W P: P le x in  D 1 
e xp re ss io n  is in d u ce d  on  tu m o r  va s c u la tu re  and  tu m o r  cells: 
a n o ve l ta rg e t fo r  d iagnosis  and  the rap y?  Cancer Res 2005, 
65:8317-8323.
23. Tamagnone L, Artigiani S, Chen H, He Z, Ming GI, Song H, Chedotal 
A, W inberg ML, Goodman CS, Poo M: P lex ins a re  a  la rg e  fa m ily  
o f  re c e p to rs  fo r  tra n s m e m b ra n e , s e c re te d , and  G P I- 
a n c h o re d  se m a p h o rin s  in v e r te b ra te s . Cell 1999, 99:71-80.
24. Gherardi E, Love CA, Esnouf RM, Jones EY: T h e  se m a  d o m a in . 
Curr Opin Struct Biol 2004, 14:669-678.
Page 9 of 10
(page number not for citation purposes)
BMC Cancer 2009, 9:297 http://www.biomedeentral.eom/1471-2407/9/297
2S.
26.
27.
28.
29.
30.
3 I.
32.
33.
34.
3S.
36.
37.
38.
39.
40.
4I .
42.
43.
44.
Rohm B, O ttem eyer A, Lohrum M, Puschel A W : P le x in /n e u ro p ilin  
co m p le x e s  m e d ia te  re p u ls io n  by  th e  a xo n a l gu id a n ce  signa l 
s e m a p h o rin  3 A . Mech Dev 2000, 93:95-104.
Nakamura F, Kalb RG, S trittm atter SM: M o le c u la r basis o f  sem a- 
p h o r in -m e d ia te d  axo n  gu id ance . J Neurobiol 2000, 44:219-229. 
Fujisawa H: D is c o v e ry  o f  s e m a p h o rin  re c e p to rs , n e u ro p ilin  
and p le x in , and  th e ir  fu n c tio n s  in n e u ra l d e v e lo p m e n t. J Neu- 
robiol 2004, 59:24-33.
Takahashi T, Fournier A, Nakamura F, Wang LH, Murakami Y, Kalb 
RG, Fujisawa H, S trittm atter SM: P le x in -n e u ro p ilin - l c o m p le xe s  
fo rm  fu n c tio n a l s e m a p h o rin -3 A  re c e p to rs . Cell 1999, 99:59-69. 
Zwaag B van der, Hellemons AJ, Leenders W P, Burbach JP, Brunner 
HG, Padberg G W , Van Bokhoven H: P L E X IN - D l,  a  n o ve l p le x in  
fa m ily  m e m b e r , is e xp ressed  in va scu la r e n d o th e liu m  and  
th e  c e n tra l n e rvo u s  sys te m  d u r in g  m o u se  e m b ryo g e n e s is . 
Dev Dyn 2002, 225:336-343.
G itler AD , Lu MM, Epstein JA: P le x in D l and  s e m a p h o rin  s igna l­
ing  a re  re q u ire d  in e n d o th e lia l ce lls  fo r  c a rd io v a s c u la r d e v e l­
o p m e n t. Dev Cell 2004, 7:107-116.
Torres-Vazquez J, G itle r AD , Fraser SD, Berk JD, Van NP, Fishman 
MC, Childs S, Epstein JA, W einstein BM: S e m a p h o r in -p le x in  s ign­
a lin g  gu ides p a tte rn in g  o f  th e  d e v e lo p in g  va s c u la tu re . Dev Cell
2004, 7:117-123.
Zhang Y, Singh MK, Degenhardt KR, Lu MM, Bennett J, Yoshida Y, 
Epstein JA: T ie 2 C re -m e d ia te d  in a c tiv a tio n  o f  p le x in D l re su lts  
in c o n g e n ita l h e a rt, v a scu la r and  s ke le ta l de fe c ts . Dev Biol
2009, 325:82-93.
Roodink I, Kats G, van Kempen L, Grunberg M, Maass C, Verrijp  K, 
Raats J, Leenders W : S e m a p h o r in  3E E xpre ss io n  C o rre la te s  
In ve rse ly  w ith  P le x in  D l  D u r in g  T u m o r  P ro g re ss io n . Am J
Pathol 2008, l7 3 :1873-1881.
Toyofuku T, Yabuki M, Kamei J, Kamei M, Makino N, Kumanogoh A, 
H ori M: S e m a p h o r in -4 A , an a c t iv a to r  fo r  T -c e ll-m e d ia te d  
im m u n ity ,  suppresses ang iogenesis  v ia  P le x in -D l.  EMBO J
2007, 26:1373-1384.
Kigel B, Varshavsky A, Kessler O, Neufeld G: Successfu l in h ib it io n  
o f  tu m o r  d e v e lo p m e n t b y  spe c ific  class-3 s e m a p h o rin s  is 
asso c ia ted  w ith  e xp re ss io n  o f  a p p ro p r ia te  s e m a p h o rin  
re c e p to rs  b y  tu m o r  cells. PLoS ONE 2008, 3:e3287.
Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, V iti F, 
Leprini A, Borsi L, Castellani P, Zardi L: Im m u n o s c in tig ra p h ic  
d e te c tio n  o f  th e  E D -B  d o m a in  o f  f ib ro n e c tin , a  m a rk e r  o f  
angiogenesis, in p a tie n ts  w ith  ca n ce r. Clin Cancer Res 2003, 
9:571-579.
Castellani P, Borsi L, Carnemolla B, Biro A, D orcaratto A, Viale GL, 
Neri D, Zardi L: D if fe re n t ia t io n  b e tw e e n  h igh - and  lo w -g ra d e  
a s tro c y to m a  using  a  h u m a n  re c o m b in a n t a n tib o d y  to  th e  
e x tr a  d o m a in -B  o f  f ib ro n e c tin . Am J Pathol 2002, l 6 l :  1695-1700. 
Schraa AJ, Kok RJ, Moorlag HE, Bos EJ, Proost JH, Meijer DK, de Leij 
LF, Molema G: T a rg e tin g  o f  R G D -m o d ifie d  p ro te in s  to  tu m o r  
va sc u la tu re : a  p h a rm a c o k in e tic  and  c e llu la r  d is tr ib u t io n  
stu d y . Int J Cancer 2002, l02:469-475.
Janssen ML, Oyen WJ, Dijkgraaf I, Massuger LF, Frielink C, Edwards 
DS, Rajopadhye M, Boonstra H, Corstens FH, Boerman OC: T u m o r  
ta rg e tin g  w ith  ra d io la b e le d  a lp h a (v )b e ta (3 ) in te g r in  b in d in g  
p e p tid e s  in a  nu de m o use  m o d e l. Cancer Res 2002, 
62:6146-6151.
Dijkgraaf I, K ruijtzer JA, Frielink C, Corstens FH, Oyen WJ, Liskamp 
RM, Boerman OC: A lp h a  v  b e ta  3 in te g r in - ta rg e t in g  o f  in tra -  
p e r ito n e a lly  g ro w in g  tu m o rs  w ith  a ra d io la b e le d  R G D  p e p­
tid e . Int J Cancer 2007, 120:605-610.
Dienst A, G runow A, Unruh M, Rabausch B, N o r JE, Fries JW, 
Gottstein C: S pec ific  o cc lu s io n  o f  m u r in e  and  h u m a n  tu m o r  
va s c u la tu re  by  V C A M - l- ta r g e te d  re c o m b in a n t fus ion  p ro ­
te in s . J Natl Cancer Inst 2005, 97:733-747.
Rafii S, Avecilla ST, Jin DK: T u m o r  v a s c u la tu re  address  b o ok: 
id e n tif ic a t io n  o f  s tag e-sp ec ific  tu m o r  vessel z ip  codes by  
phage d isp lay . Cancer Cell 2003, 4:331-333.
Kuroda H, Tamaru J, Sakamoto G, Ohnisi K, Itoyama S: Im m u -  
n o p h e n o ty p e  o f  ly m p h o c y tic  in f i lt r a t io n  in m e d u lla ry  c a rc i­
n o m a  o f  th e  b re a s t. Virchows Arch 2005, 446:10-14. 
Saravanamuthu J, Reid W M , George DS, C ro w  JC, Rolfe KJ, MacLean 
AB, P erre tt C W : T h e  ro le  o f  ang iogenesis  in v u lv a r  ca n ce r, v u l­
v a r  in tra e p ith e lia l neop las ia , and  v u lv a r  lich en  sc lerosus as 
d e te rm in e d  b y  m ic ro ve sse l d e n s ity  analysis. Gynecol Oncol 
2003, 89:251-258.
45. Gambino LS, W re fo rd  NG, Bertram JF, Dockery P, Lederman F, Rog­
ers PA: A n g io g e n e s is  o ccu rs  b y  vessel e lo n g a tio n  in p ro life ra ­
t iv e  phase h u m a n  e n d o m e tr iu m . Hum Reprod 2002, 
17:1199-1206.
Pre-pub lica tion  h istory
The pre-publication history for this paper can be accessed 
here:
http://www.biomedcentral.cOm/1471-2407/9/297/pre
pub
Publish w ith  B io Med Central and every 
scientist can read your w ork  free o f charge
"BioMed Central w ill be the most significant development fo r  
disseminating the results o f  biomedical research in ou r life tim e ." 
Sir Paul Nurse, Cancer Research UK
Y o u r research papers w i ll  be:
• available free of charge to  the entire biomedical community
• peer reviewed and published immediately upon acceptance
• cited in PubMed and archived on PubMed Central
• yours — you keep the copyright
S ub m it y o u r m a n uscrip t here:
http://www.biomedcentral.com/info/publishing_adv.asp oB ioM e d central
Page 10 of 10
(page number not for citation purposes)
